Skip to main content
. 2019 Oct 22;13(12):2679–2696. doi: 10.1002/1878-0261.12582

Figure 2.

Figure 2

Animacroxam induces ‘cap formation’ and suppresses glucose uptake in inoculated TGCT plaques. (A) T1w and T2w images of control‐, animacroxam‐, and cisplatin‐treated tumor plaques. Animacroxam‐treated tumors show a distinct viable tumor core (dark in T1w‐/bright in T2w images) and a necrotic cap (bright in T1w‐/dark in T2w images). (B) T1w and corresponding PET‐MR images of 18F‐FDG uptake in tumor plaques treated with NaCl, animacroxam, or cisplatin. (C) Animacroxam (5.0 µm)‐ and cisplatin (2.5 µm)‐treated tumor plaques showed a reduced uptake of 18F‐FDG. Results are shown as means ± SEM of at least n = 3 independent experiments. Scale bar = 1 cm. *P‐values of ≤ 0.05, unpaired t‐test.